MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

MC

503.3

-0.49%↓

SANES

6.906

+0.57%↑

BNP

79.33

-0.54%↓

BBVA

13.38

+0.22%↑

INGA

18.93

+0.39%↑

Search

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

199.35 0.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

197.5

Max

200.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

75M

115M

Pardavimai

-6.7M

745M

P/E

Sektoriaus vid.

96.256

24.598

Pelnas, tenkantis vienai akcijai

1.16

Dividendų pajamingumas

0.34

Pelno marža

15.498

Darbuotojai

9,961

EBITDA

124M

256M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.68% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.34%

4.30%

Kitas uždarbis

2025-07-22

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.3B

21B

Ankstesnė atidarymo kaina

198.95

Ankstesnė uždarymo kaina

199.35

Naujienos nuotaikos

By Acuity

37%

63%

128 / 540 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-15 22:52; UTC

Uždarbis
Pagrindinės rinkos jėgos

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

2025-05-15 20:37; UTC

Svarbiausios naujienos
Uždarbis

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

2025-05-16 00:00; UTC

Rinkos pokalbiai

Xero Bull Stays Positive on Cost Outlook -- Market Talk

2025-05-15 23:47; UTC

Rinkos pokalbiai

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-15 23:38; UTC

Rinkos pokalbiai

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

2025-05-15 23:14; UTC

Svarbiausios naujienos

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

2025-05-15 22:46; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

2025-05-15 22:46; UTC

Įsigijimai, susijungimai, perėmimai

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

2025-05-15 21:58; UTC

Uždarbis

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

2025-05-15 21:24; UTC

Uždarbis

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

2025-05-15 20:56; UTC

Rinkos pokalbiai

U.S. Spending Downturn Could Lie Ahead -- Market Talk

2025-05-15 20:54; UTC

Rinkos pokalbiai
Uždarbis

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

2025-05-15 20:54; UTC

Uždarbis

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

2025-05-15 20:51; UTC

Uždarbis

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

2025-05-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-05-15 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

2025-05-15 20:50; UTC

Uždarbis

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

2025-05-15 20:47; UTC

Uždarbis

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

2025-05-15 20:37; UTC

Uždarbis

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

2025-05-15 20:26; UTC

Svarbiausios naujienos

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

2025-05-15 20:25; UTC

Uždarbis

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

20.68% į viršų

12 mėnesių prognozė

Vidutinis 239.13 EUR  20.68%

Aukščiausias 250 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

5

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

128 / 540 reitingas Finansų sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.